Adaptive supportive ventilation in a child with coronavirus pneumonia and diabetes mellitus

Дмитріев, Д В; Dobrovanov, Oleksandr; Kralinský, K.; Babela, R.

doi:10.21508/1027-4065-2020-65-5-66-72

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the European Union level, the safety profile of registered vaccines has been shown to be largely in accordance with the drug dossier and the benefits of the vaccine far outweigh any potential risks. In addition to symptomatic treatment, patients with a more severe course of the disease require hospitalisation, supportive oxygen therapy (administration of oxygen), and in cases that are even more severe than that must be put on MLV [41][42][43].…”

Section: Adverse Effects Of Vaccinesmentioning

confidence: 99%

Pain in COVID-19: Quis est culpa?

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: At present, during the coronavirus disease (COVID-19) pandemic, chronic pain is becoming more prominent, and it is also associated with the post-COVID-19 syndrome. Thanks to quick decisions on the therapy and as part of COVID-19 prevention, we have succeeded in stabilising the situation all over the world. On the other hand, ‘quick decisions’ have contributed to other significant issues which we are beginning to deal with now: in the effort to defeat the virus, many experts regarded the adverse effects of the medications used to be of secondary importance. Purpose: The article aims to demonstrate the side effects of treatment with various drugs (and their combinations) that are used to treat COVID-19 disease. Method: From the beginning of January until mid-May, the COVID-19 department of the 2nd Surgical Clinic of the Faculty of Medicine of the Comenius University in Bratislava (University Hospital Bratislava, Hospital of Saints Cyril and Methodius) treated 221 patients with moderate and severe course of COVID-19 (2nd wave of the pandemic). We saw some adverse effects and lack of effect of certain drugs for COVID-19. Results: The benefits of preventive measures compared to treatment are enormous. For example, corticoids can impair metabolism, cause diabetes, or suppress immunity. Antibiotics may cause colitis and blood pressure medications may negatively impact blood circulation. Conclusion: Preventive measures such as vaccination and activation of intrinsic antiviral immune systems are based on an incomparable benefit. Important in the process of the activation of antiviral immunity (linked to interferon synthesis) in the prevention of COVID-19 is the improvement of vitamin D deficit and the use of other micronutrients. Practical value: The results of the study will be valuable in the field of medicine, for virologists, pharmacologists, pharmacists, and medical professionals.

show abstract

Section: Adverse Effects Of Vaccinesmentioning

confidence: 99%

Pain in COVID-19: Quis est culpa?

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the European Union level, the safety profi le of registered vaccines has been shown to be largely in accordance with the drug dossier and the benefi ts of the vaccine far outweigh any potential risks. In addition to symptomatic treatment, patients with a more severe course of the disease require hospitalisation, supportive oxygen therapy (administration of oxygen), and cases that are even more severe than that must be put on mechanical lung ventilation (MLV) (41)(42)(43).…”

Section: Adverse Effects Of Vaccinesmentioning

confidence: 99%

Chronic pain in post-COVID syndrome

Dobrovanov¹,

Dmytriiev²,

Prochotský³

et al. 2023

BLL

View full text Add to dashboard Cite

Our body senses two types of pain, acute and chronic. Acute pain lasts for a short time. It occurs when our body wants to protect us from a dangerous situation. This way, our nerves are telling us that something is wrong. But if some time passes since our injury, treatment or surgery and the pain or discomfort persists, we are speaking of chronic pain. It is often diffi cult to determine its intensity or even prove its existence. The discomfort and pain are not relieved and physical pain may be accompanied by mental issues. At present, during the COVID-19 pandemic, chronic pain is becoming more prominent, and it is also associated with the post-COVID syndrome. In their efforts to help patients suffering from COVID-19, many new treatment protocols have been prepared and various antiviral drugs and other potentially useful drugs have been used (often without prior approval or testing). Basically, it was a kind of 'experimental' treatment. At present, thanks to quick therapy decisions and as part of COVID-19 prevention, we have succeeded in stabilising the situation all over the world. A relatively fast development of vaccines against SARS-CoV-2 with a view to achieve collective immunity has greatly contributed to this. On the other hand, 'quick decisions' have contributed to other signifi cant issues which we are beginning to deal with now, i.e, in the effort to defeat the virus, many experts regarded the adverse effects of the medications used to be of secondary importance. In the article we would like to point out the other side of the 'successful' treatment of COVID-19, namely the possible iatrogenic conditions which signifi cantly contribute to the post-COVID-19 syndrome and chronic pain. The importance of preventive measures over uncertain result of COVID-19 treatment is emphasised (Tab. 4, Fig. 1, Ref. 50).

show abstract

Efficacy of Combination of Tiotropium/Olodaterol in Patients With Copd in Real Clinical Practice

et al. 2022

View full text Add to dashboard Cite

The aim: Show the efficacy of the Tiotropium / olodaterol combination in real clinical practice. Materials and methods: 100 patients with the diagnosis of COPD were included onto the study during the period of 2019-2020, an average age was 64.09±1.94 years, 66 were men (66 %) and 34 were women (34 %). There were 68 % of smokers with the average smoking experience of 24.44±4.84 pack-years. Average COPD duration was 9.35±2.42 years. There were 3 visits in the study – visit 1 (baseline), visit 2 (4-6 weeks) visit 3 (1 year). Source documentation was assessed at visit 1 and visit 3 for amount of exacerbations, antibiotic, glucocorticosteroid, methylxanthines use; mMRC and CAT were assessed at all visits. Results: Combined therapy with tiotropium/olodaterol improves clinical course of COPD, which is characterized by the significant decreased of the amount of exacerbations (2.63±0.29 to 1.63±0.21) and hospital admissions (1.2±0.2 tо 0.37±0.11). Improvement of symptoms and amount of exacerbation leads to much less use of antibiotics and glucocorticosteroids. A part of patients that used antibiotics decreased from 86±6.9 % to 67±9.3 %, amount of antibiotic courses from 1.37±0.17 tо 0.88±0.15, duration of treatment with antibiotics from 10.85±1.53 to 6.12±1.17 days. Part of the patients that used glucocorticosteroids decreased from 50±9.9 % tо 30±9.1 %, duration of treatment with antibiotics reduced from 3.97±1.06 tо 1.86±0.91 days. There also was a tendency towards a lesser used of methylxanthines. Combined therapy with tiotropium/olodaterol significantly decreased symptoms of COPD according to the mMRC (2.3±0.14 to 1.87±0.15) and САТ (23.28±1.71 to 15.77±1.58). Conclusions: Tiotropium/olodaterol combination showed its efficacy in real clinical practice. There was significant reduction in amount of exacerbation and antibiotic, gluco¬corticosteroid use during the study, which was also accompanied by the reduction is symptoms.

show abstract

Adaptive supportive ventilation in a child with coronavirus pneumonia and diabetes mellitus

Cited by 3 publications

References 32 publications

Pain in COVID-19: Quis est culpa?

Pain in COVID-19: Quis est culpa?

Chronic pain in post-COVID syndrome

Efficacy of Combination of Tiotropium/Olodaterol in Patients With Copd in Real Clinical Practice

Contact Info

Product

Resources

About